Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for leukemia patients too sick for chemo?

NCT ID NCT04150029

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a new drug called sabatolimab combined with two other drugs (azacitidine and venetoclax) in 90 adults with acute myeloid leukemia who were not healthy enough for intensive chemotherapy. The goal was to see if the combination could help patients achieve remission. However, the study was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sabatolimab (MBG453) plus azacitidine and venetoclax
What this could lead to
If successful, this combination could offer a new treatment option for AML patients who cannot tolerate standard chemotherapy.
What could go wrong
The trial was terminated early, so results are limited. It is a phase 2 study, and the combination may cause serious side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

  • 25Uni of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • Chattanooga Onc And Hem Assoc PC

    Chattanooga, Tennessee, 37404, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Duke Univ Medical Center

    Durham, North Carolina, 27710, United States

  • Huntsman Cancer Institute Univ of Utah

    Salt Lake City, Utah, 84112 0550, United States

  • Levine Cancer Insitute Carolinas Healthcare System

    Charlotte, North Carolina, 28204, United States

  • MD Anderson Cancer Center University of Texas

    Houston, Texas, 77030, United States

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States

  • Memorial Sloan Kettering

    New York, New York, 10017, United States

  • Novartis Investigative Site

    Clayton, Victoria, 3168, Australia

  • Novartis Investigative Site

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Novartis Investigative Site

    Toronto, Ontario, M5G 2M9, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H3T 1E2, Canada

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Leipzig, Saxony, 04103, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Milan, MI, 20162, Italy

  • Novartis Investigative Site

    Roma, RM, 00133, Italy

  • Novartis Investigative Site

    Fukushima, Fukushima, 960 1295, Japan

  • Novartis Investigative Site

    Yamagata, Yamagata, 990 9585, Japan

  • Novartis Investigative Site

    Seoul, Seocho gu, 06591, South Korea

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Kaohsiung City, 83301, Taiwan

  • Uni Of Iowa Hospitals And Clinics

    Iowa City, Iowa, 52242, United States

  • Weill Cornell Medicine NY-Presb

    New York, New York, 10021, United States

  • Yale University School Of Medicine

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.